Latest Breaking News On - Enfortumab vedotin - Page 3 : comparemela.com

Gilead and Kite Oncology to Highlight Broad and Diverse Oncology Portfolio at ASCO 2024

ADCs and Immunotherapy Broaden the Bladder Cancer Treatment Paradigm

Jonathan E. Rosenberg, MD, discusses how recent FDA approvals have revolutionized the treatment paradigm for locally advanced or metastatic bladder cancer.

Dr Bellmunt on the Impact of Treatment With Enfortumab Vedotin Plus Pembrolizumab in Urothelial Cancer

Joaquim Bellmunt, MD, PhD, discusses how the FDA approval of enfortumab vedotin plus pembrolizumab impacts the urothelial cancer treatment paradigm.

Innate Pharma SA: Innate Pharma Presents at AACR 2024 Preclinical Efficacy of Its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate

Experts Discuss Current Standards, Selection, and Uncertainties in Bladder and Renal Cancer Care

Experts delineate the latest developments and lingering questions in bladder and renal cancers, covering pivotal trials, emerging therapies, and optimal management approaches.